Estradiol 1mg / Drospirenone 2mg tablets

Heavy menstrual bleeding (HMB) is a common gynecological condition among women of reproductive age that significantly affects quality of life and often leads to iron deficiency anemia. Hormonal treatments are usually prescribed in combination to include combined oral contraceptives (COCs) and progestin-only pills (POPs) in treating HMB. This systematic review aims to compare the effectiveness and safety of COCs and POPs in the management of HMB in terms of menstrual blood loss, hemoglobin levels, side effects, and patient satisfaction. The literature search was conducted on PubMed, Scopus, Web of Science, and Google Scholar and covered articles published between 2000 and 2025. Blood loss reduction, hemoglobin levels, side effects, and patient satisfaction data were extracted, and a narrative review was conducted. The review included 10 studies. Both POPs and COCs had a great impact on minimizing menstrual blood loss and enhancing hemoglobin index. There were no mean differences in the two treatments concerning the improvement of hemoglobin, with a mean change of 2.75-2.71 g/dL in both treatment groups (p = 0.84). The heterogeneity within the companies made the calculation of confidence intervals impossible, and the comparison was done regarding the differences in mean only. COCs were linked with an increased incidence of nausea, headaches, and weight gain, whereas POPs were found to have more desirable side effects. Drospirenone (POP) showed reduced unscheduled bleeding days and patient satisfaction with the medication compared to other POPs. Risk of bias was moderate to low across studies, with some concerns regarding randomization and blinding in certain trials. Further research with larger sample sizes, longer follow-up periods, and head-to-head comparisons between COCs and POPs is needed to confirm these findings and evaluate the long-term impact of these treatments.

Abstract licence: CC BY

ObjectiveTo evaluate the hemostatic profile of estetrol/drospirenone (E4/DRSP) compared with ethinylestradiol/drospirenone (EE/DRSP) in adult women.MethodsA systematic review and meta-analysis of randomized controlled trials (RCTs) was performed according to PRISMA guidelines. Eligible studies compared E4/DRSP with EE/DRSP in adult women and assessed coagulation, anticoagulation, or fibrinolytic markers. Three RCTs (n=183) met inclusion criteria. Data were extracted independently, and pooled mean differences (MD) were calculated using random-effects models.ResultsCompared to EE/DRSP, E4/DRSP was associated with higher protein S activity (MD = 21.23; 95% CI: 11.83 to 30.64; pConclusionE4/DRSP demonstrates a more favorable hemostatic profile than EE/DRSP, potentially reducing thrombotic risk. Despite the limited number of RCTs, consistency across markers supports E4 as a safer estrogenic component for contraceptive formulations, with implications for women at increased risk of venous thromboembolism.PROSPERO registry: #CRD420251074961.

Abstract licence: CC BY

According to the FDA Guidance for Industry on Clinical Drug Interaction (DDI) Studies with Combined Oral Contraceptives (COCs), sponsors are expected to conduct dedicated clinical DDI studies if in vitro findings suggest weak or moderate CYP3A induction, while concomitant use of COCs with strong inducers should be avoided. The guidance further suggests that a negative DDI result for drospirenone (DRSP) may be extrapolated to other progestins that are less sensitive to CYP3A modulation, such as levonorgestrel (LNG). This approach assumes that DDI-mediated changes in exposure directly translate into clinical efficacy across progestins. To evaluate the validity of this assumption, we established a quantitative link between dose, exposure, and response (Pearl Index [PI] and ovulation rate [OR]) via an integrated model-based meta-analysis, physiologically based pharmacokinetic, and pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation approach using data from 51 clinical studies in 36,040 women receiving LNG or DRSP. COCs containing LNG and DRSP were selected because they represent clinically relevant progestins at the lower and the upper end of the fraction metabolized via CYP3A4. The results of our analysis show a moderate correlation (Pearson's r = 0.52, 95% CI 0.46-0.58, P < 0.001) between PI and OR, which enables the use of OR as an ethically measurable endpoint, even at subtherapeutic doses/exposures, to predict efficacy outcomes. They further show that DDI-induced changes in exposure do not directly translate into clinical response. Therefore, DDIs with COCs should be interpreted in a PK/PD rather than a PK-only context. The quantitative framework developed in this study can serve as the scientific basis to do so.

Abstract licence: CC BY

Delayed-start contraception may reduce the risk of unintended pregnancy; however, data on newer formulations, such as estetrol (E4)-containing pills are limited. Therefore, this study aimed to evaluate the effectiveness of delayed start combined oral contraceptives (COCs) containing 15 mg E4 and 3 mg drospirenone (E4/DRSP). In this randomized, single-blind, non-inferiority trial, 36 healthy women aged 18–45 years with regular menstrual cycles were assigned to receive either E4/DRSP or 20 µg ethinyl estradiol/75 µg gestodene (EE/GS), starting treatment between cycle day 7 and 9. The primary outcome was ovulation inhibition, assessed using the modified Hoogland score. The secondary outcomes included cervical mucus changes and adverse effects. Baseline characteristics did not differ significantly between the groups. The mean age and menstrual cycle length were 38.75 ± 5.8 years and 28.67 ± 1.96 days, respectively. More than half (55.56%) of the participants began COC use on day 9, with 50% of them showing active follicular development at baseline (Hoogland score of 4). Ovulation was inhibited in 61.11% of participants in both groups (adjusted relative risks: 0.95, 95% confidence interval [CI]: 0.56–1.59, p = 0.841, and absolute risk difference: −0.03, 95% CI: −0.39 to 0.33). Approximately half of the participants who ovulated showed ovarian activity that was not associated with theoretical pregnancy risk. Cervical mucus profiles and adverse events, including unscheduled bleeding, did not differ significantly between the groups. Initiating E4/DRSP on cycle day 7–9 appears comparable to that of EE/GS for ovulation inhibition; however, high ovulation rates limit the confirmation of non-inferiority. Clinical trial registration: ClinicalTrials.gov Registration on April 25, 2024 (ID: NCT06396221; https://clinicaltrials.gov/study/NCT06396221).

Abstract licence: CC BY-NC-ND